Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3025876 · 1 trial · 1 indication
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| LY3025876 | EXPERIMENTAL | Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days. |
| Placebo | PLACEBO_COMPARATOR | Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days |
| LY3025876 + Liraglutide | EXPERIMENTAL | Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Placebo + Liraglutide | PLACEBO_COMPARATOR | Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3025876 | DRUG | Administered SQ |
| Placebo | DRUG | Administered SQ |
| Liraglutide | DRUG | Administered SQ |
Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM) as determined by the investigator, controlled with diet or exercise alone or on a stable dose of metformin for at least 30 days * Have a body mass index (BMI) greater than or equal to 23 and less than or equal to 45 kilograms per sq...
LY3025876 is an investigational small molecule developed by Eli Lilly and Company for the treatment of Type 2 Diabetes Mellitus. It is a Phase 1 clinical candidate in the metabolic therapeutic area. It has been studied in a single completed Phase 1 trial and is not approved for any use.
LY3025876 was studied as a potential treatment for Type 2 Diabetes Mellitus. Its only clinical trial enrolled 72 adult participants with diabetes in the United States. Because development remains at Phase 1, LY3025876 is investigational and has no approved indication in Type 2 Diabetes Mellitus or any other condition.
LY3025876 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in participants with Type 2 Diabetes Mellitus.
LY3025876 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA or any other regulatory agency for Type 2 Diabetes Mellitus or any other indication.
LY3025876 has been evaluated in one completed Phase 1 trial, NCT01870297, titled A Study of LY3025876 in Participants With Diabetes. The trial enrolled 72 participants aged 21 years and older in the United States. It was randomized, double-blind, and placebo-controlled, and no trials are currently active.